Citius Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
CTXR$0.49-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
| Exhibit Number · Description of Document · Registrant’s Form · Dated · Exhibit Number · Filed Herewith | ||||
|---|---|---|---|---|
| 2.1+ | Agreement and Plan of Merger, dated as of October 23, 2023, by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition, and TenX Merger Sub Inc. | 8-K | 10/24/2023 | 2.1 |
| 3.1 | Amended and Restated Articles of Incorporation of Citius Pharmaceuticals, Inc. | 8-K | 9/18/2014 | 3.1 |
| 3.2 | Certificate of Amendment to the Amended and Restated Articles of Incorporation of Citius Pharmaceuticals, Inc., effective September 16, 2016. | 8-K | 9/21/2016 | 3.1 |
| 3.3 | Certificate of Amendment to the Amended and Restated Articles of Incorporation of Citius Pharmaceuticals, Inc., effective June 9, 2017. | 8-K | 6/8/2017 | 3.1 |
| 3.4 | Certificate of Amendment to the Articles of Incorporation of Citius Pharmaceuticals Inc., dated June 21, 2021. | 8-K/A | 6/22/2021 | 3.1 |
| 3.5 | Amended and Restated Bylaws of Citius Pharmaceuticals, Inc. | 8-K | 2/9/2018 | 3.1 |
| 3.6 | Certificate of Change filed with the Secretary of State of Nevada on November 22, 2024. | 8-K | 11/26/2024 | 3.1 |
| 4.1 | Form of Common Stock Purchase Warrant, dated August 13, 2018, as amended August 8, 2023. | 10-K | 12/29/2023 | 4.1 |
| 4.2 | Form of Pre-Funded Common Stock Purchase Warrant, dated August 13, 2018. | 8-K | 8/13/2018 | 4.2 |
| 4.3 | Form of Underwriter’s Common Stock Purchase Warrant, dated August 13, 2018, as amended August 8, 2023. | 10-K | 12/29/2023 | 4.3 |
| 4.4 | Form of Investor Warrant issued April 3, 2019. | 8-K | 4/03/2019 | 4.1 |
| 4.5 | Form of Placement Agent Warrant issued April 3, 2019. | 8-K | 4/03/2019 | 4.2 |
| 4.6 | Form of Common Stock Purchase Warrant issued September 27, 2019. | 8-K | 9/27/2019 | 4.1 |
| 4.7 | Form of Underwriters Common Stock Purchase Warrant issued September 27, 2019. | 8-K | 9/27/2019 | 4.3 |
| 4.8 | Form of Investor Warrant issued on February 19, 2020. | 8-K | 2/19/2020 | 4.1 |
| 4.9 | Form of Placement Agent Warrant issued on February 19, 2020. | 8-K | 2/19/2020 | 4.2 |
| 4.10 | Form of Investor Warrant issued May 18, 2020. | 8-K | 5/18/2020 | 4.1 |
| 4.11 | Form of Placement Agent Warrant issued May 18, 2020. | 8-K | 5/18/2020 | 4.2 |
| 4.12 | Form of Underwriter Warrant issued August 10, 2020. | 8-K | 8/10/2020 | 4.1 |
| 4.13 | Form of Investor Warrant issued January 27, 2021. | 8-K | 1/27/2021 | 4.1 |
| 4.14 | Form of Placement Agent Warrant issued January 27, 2021. | 8-K | 1/27/2021 | 4.2 |
| Exhibit Number | Description of Document | Registrant’s Form | Dated | Exhibit Number | Filed Herewith |
|---|---|---|---|---|---|
| 4.15 | Form of Registration Rights Agreement, dated January 24, 2021, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto. | 8-K | 1/27/2021 | 4.3 | |
| 4.16 | Form of Investor Warrant issued February 19, 2021. | 8-K | 2/19/2021 | 4.1 | |
| 4.17 | Form of Placement Agent Warrant issued February 19, 2021 | 8-K | 2/19/2021 | 4.2 | |
| 4.18 | Form of Warrant issued May 8, 2023. | 8-K | 5/8/2023 | 4.1 | |
| 4.19 | Form of Placement Agent Warrant issued May 8, 2023. | 8-K | 5/8/2023 | 4.2 | |
| 4.20 | Form of Investor Warrant issued April 30, 2024. | 8-K | 4/30/2024 | 4.1 | |
| 4.21 | Form of Investor Warrant issued November 18, 2024. | 8-K | 11/18/2024 | 4.1 | |
| 4.22 | Description of Common Stock. | X | |||
| 10.1* | Citius Pharmaceuticals, Inc. 2014 Stock Incentive Plan. | 10-Q | 8/15/2016 | 10.1 | |
| 10.2* | Form of Citius Pharmaceuticals, Inc. 2014 Stock Incentive Plan Nonqualified Stock Option. | 10-Q | 8/15/2016 | 10.2 | |
| 10.3* | Amended and Restated Employment Agreement between Myron Holubiak and Citius Pharmaceuticals, Inc., executed April 12, 2022, effective May 1, 2022. | 10-Q | 5/12/2022 | 10.1 | |
| 10.4 | Second Amendment to the Patent and Technology License Agreement between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc., dated March 20, 2017. | 10-Q | 5/15/2017 | 10.8 | |
| 10.5* | Amended and Restated Employment Agreement between Leonard Mazur and Citius Pharmaceuticals, Inc., dated October 19, 2017. | 10-K | 12/11/2018 | 10.23 | |
| 10.6* | Employment Agreement between Jaime Bartushak and Citius Pharmaceuticals, Inc., dated November 27, 2017. | 8-K | 12/1/2017 | 10.1 | |
| 10.7* | Citius Pharmaceuticals, Inc. 2018 Omnibus Stock Incentive Plan | 10-Q | 2/14/2018 | 10.2 | |
| 10.8 | Form of Securities Purchase Agreement between Citius Pharmaceuticals, Inc. and the purchasers named therein, dated March 28, 2018. | 8-K | 3/29/2018 | 10.1 | |
| 10.9+ | Patent and Technology License Agreement, dated January 2, 2019, between the Board of Regents of the University of Texas System on behalf of the University of Texas M. D. Anderson Cancer Center and Citius Pharmaceuticals, Inc. | 10-Q | 2/14/2019 | 10.1 | |
| 10.10 | First Amendment, dated October 15, 2015, to Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc. | 10-Q | 2/14/2019 | 10.2 | |
| 10.11+ | Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc. | 10-Q | 5/12/2023 | 10.1 | |
| Exhibit Number · Description of Document · Registrant’s Form · Dated · Exhibit Number · Filed Herewith | ||||
|---|---|---|---|---|
| 10.12 | Form of Securities Purchase Agreement, dated April 1, 2019, by and between Citius Pharmaceuticals, Inc. and the purchasers named therein. | 8-K | 4/03/2019 | 10.1 |
| 10.13* | Citius Pharmaceuticals, Inc. 2020 Omnibus Stock Incentive Plan. | Schedule 14A | 12/20/2019 | Appendix A |
| 10.14* | Form of Notice of Stock Option Grant and Stock Option Award Agreement. | 10-Q | 2/13/2020 | 10.2 |
| 10.15 | Form of Warrant Exercise Agreement, dated February 14, 2020, by and between Citius Pharmaceuticals, Inc. and the investor signatory thereto. | 8-K | 2/19/2020 | 10.1 |
| 10.16 | Form of Warrant Exercise Agreement, dated February 14, 2020, by and between Citius Pharmaceuticals, Inc. and the investor signatory thereto. | 8-K | 2/19/2020 | 10.2 |
| 10.17 | Form of Securities Purchase Agreement, dated May 14, 2020, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto. | 8-K | 5/18/2020 | 10.1 |
| 10.18* | Employment Agreement, effective as of July 14, 2020, between Citius Pharmaceuticals, Inc. and Myron Czuczman. | 10-Q | 8/14/2020 | 10.3 |
| 10.19+ | License Agreement, dated October 6, 2020, between NoveCite, Inc. and Novellus Therapeutics, Limited. | 10-K | 12/16/2020 | 10.24 |
| 10.20 | Form of Securities Purchase Agreement, dated January 24, 2021, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto. | 8-K | 1/27/2021 | 10.1 |
| 10.21 | Form of Securities Purchase Agreement, dated February 16, 2021, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto. | 8-K | 2/19/2021 | 10.1 |
| 10.22* | Citius Pharmaceuticals, Inc. 2021 Omnibus Incentive Stock Plan. | Schedule 14A | 4/12/2021 | Appendix B |
| 10.23* | Form of Notice of Stock Option Grant and Stock Option Award Agreement. | 10-K | 12/15/2021 | 10.29 |
| 10.24+ | Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy’s Laboratories S.A. and Citius Pharmaceuticals, Inc. | 10-K | 12/15/2021 | 10.30 |
| 10.25+ | Amended and Restated License, Development and Commercialization Agreement, dated as of February 26, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | 10-K | 12/15/2021 | 10.31 |
| 10.26+ | Amendment to Amended and Restated License, Development and Commercialization Agreement, dated as of August 9, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | 10-K | 12/15/2021 | 10.32 |
| 10.27+ | Amendment No. 2 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 31, 2021, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A. | 10-K | 12/15/2021 | 10.33 |
| 10.28 | Citius Pharmaceuticals, Inc. 2023 Omnibus Stock Incentive Plan. | Schedule 14A | 12/22/2022 | Annex A |
| 10.29 | Form of Securities Purchase Agreement, dated May 3, 2023, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto. | 8-K | 5/8/2023 | 10.1 |
| 10.30+ | Sponsor Support Agreement, dated as of October 23, 2023, by and among 10XYZ Holdings LP, TenX Keane Acquisition, Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. | 8-K | 10/24/2023 | 10.1 |
| Exhibit Number | Description of Document | Registrant’s Form | Dated | Exhibit Number | Filed Herewith |
|---|---|---|---|---|---|
| 10.31+ | Form of Amended and Restated Registration Rights Agreement. | 8-K | 10/24/2023 | 10.2 | |
| 10.32+ | Form of Amended and Restated Shared Services Agreement. | 8-K | 10/24/2023 | 10.3 | |
| 10.33+ | Form of Securities Purchase Agreement, dated as of April 25, 2024, by and among Citius Pharmaceuticals, Inc. and the investors signatory thereto. | 8-K | 4/30/2024 | 10.1 | |
| 10.34+ | Amended and Restated Shared Services Agreement, dated, August, 12, 2024, between Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. | 8-K | 8/16/2024 | 10.1 | |
| 10.35+ | Amended and Restated Registration Rights Agreement, dated as of August 12, 2024, by and between Citius Oncology, Inc. and the signatories thereto. | 8-K | 8/16/2024 | 10.2 | |
| 10.36+ | Side Letter Agreement, dated August 12, 2024, by and by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc. | 8-K | 8/16/2024 | 10.3 | |
| 10.37+ | Promissory note, dated August 16, 2024, issued to Citius Pharmaceuticals, Inc. by Citius Oncology, Inc. | 8-K | 8/16/2024 | 10.4 | |
| 10.38 | Form of Securities Purchase Agreement, dated as of November 15, 2024, by and among Citius Pharmaceuticals, Inc. and the investors signatory thereto. | 8-K | 11/18/2024 | 10.1 | |
| 19.1 | Insider Trading Policy. | -- | -- | -- | X |
| 21 | Subsidiaries. | 10-K | 12/29/2023 | 21 | |
| 23.1 | Consent of Independent Registered Public Accounting Firm. | -- | -- | -- | X |
| 31.1 | Certification of the Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a). | -- | -- | -- | X |
| 31.2 | Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a). | -- | -- | -- | X |
| 32.1 | Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002. | -- | -- | -- | X |
| EX-101.INS | INLINE XBRL INSTANCE DOCUMENT | -- | -- | -- | X |
| EX-101.SCH | INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | -- | -- | -- | X |
| EX-101.CAL | INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE | -- | -- | -- | X |
| EX-101.DEF | INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE | -- | -- | -- | X |
| EX-101.LAB | INLINE XBRL TAXONOMY EXTENSION LABELS LINKBASE | -- | -- | -- | X |
| EX-101.PRE | INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE | -- | -- | -- | X |
| 104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). | ||||
| + | Portions of this exhibit have been omitted pursuant to Item 601(b)10 of Regulation S-K or certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2) or 601(a)(5), as applicable. Citius Pharma agrees to furnish supplementally an unredacted copy such exhibit, including any omitted exhibits and schedules, to the SEC upon its request. |
|---|
| * | Management contract or compensatory plan. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.